Tranzyme Pharma Inc.'s drug ulimorelin failed to perform in a trial for bowel resection recovery acceleration, according to top-line results released Monday.
If early human trial results from Inflammagen Therapeutics Inc. are borne out in its new Phase II pilot study, disclosed Monday, the company could have a major blockbuster on its hands, according to CEO John Rodenrys.
Mersana Therapeutics Inc. is cashing in on the rage for antibody-drug conjugates (ADCs) in a new collaboration agreement with Endo Pharmaceuticals Inc.
Millennium, a unit of Takeda Pharmaceutical Co. Ltd., may soon be able to add peripheral T-cell lymphoma (PTCL) to its list of cancers that can be treated with its investigational Aurora A kinase inhibitor, MLN8237 (alisertib).
VANCOUVER, British Columbia – Most of the companies represented at the BioPartnering North America meeting earlier this week either were looking for opportunities to invest in, or looking to find investments.
VANCOUVER, British Columbia – In the near future, Asian markets of the Pacific Rim region, including China, will contribute 40 percent of overall global pharmaceutical industry growth, which is expected to reach $156 billion annually by 2014, despite growing price interventions, according to Technology Visions Group LLC partner Robert Kilpatrick, who led a leadership session on Pacific Rim dealmaking at the BioPartnering North America conference.
VANCOUVER, British Columbia – In the near future, Asian markets of the Pacific Rim region, including China, will contribute 40 percent of overall global pharmaceutical industry growth, which is expected to reach $156 billion annually by 2014, despite growing price interventions, according to Technology Visions Group LLC partner Robert Kilpatrick, who led a leadership session on Pacific Rim dealmaking at the BioPartnering North America conference.
VANCOUVER, British Columbia – With delegates from biotech and pharma companies attending the BioPartnering North America conference keenly focused on dealmaking opportunities for 2012 and beyond, Deloitte Recap LLC provided perspective on the first day of the 10th annual meeting by breaking down that activity for the previous year.
YM Biosciences Inc. has enjoyed a sustained boost to its stock value since reporting positive Phase I/II results for JAK/JAK2 kinase inhibitor CYT387 in December 2011.
